Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients

Abstract

Background:BRAFV600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC.Methods: We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with BRAF mutated CRC. Patients were classified according to BRAF status as BRAFV600E mutation and non-V600E mutations. Difference of characteristics and survival between the two groups was analyzed.Results: There was no significant difference in gender, family history, location of primary tumor, metastatic sites between patients with BRAF-V600E mutation and non-V600E mutations. Patients with V600E mutation were younger than those with non-V600E mutations (p = 0.002). Patients with BRAFV600E mutation showed a poorer outcome than those with non-V600E mutations (23.1 vs. 49.9 months, respectively, p = 0.0024). Lack of CDX2 expression was associated with worse prognosis (mOS: 9.4 m vs. not reached, respectively, p = 0.016). Status of V600E mutation did not affect the mPFS and ORR of first-line or second-line treatment.Conclusion:BRAFV600E mutation defines a distinct subgroup of CRC with worse prognosis. Lack of CDX2 expression is associated with poor OS. Status of V600E mutation did not affect the mPFS of first-line or second-line treatment.

The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer

“…4 B). BRAF mutations have been associated with worse prognosis in diverse cancers [43] , [44] . In CESC, ESCA, STAD, and THCA, BRAF -mutated tumors had significantly higher SP scores than BRAF -wildtype tumors ( P < 0.05) ( Fig.…”

Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literature

“…Patients with BRAF V600E mutation have been reported to have the worst prognosis among all BRAF mutations [7] [22,23]. Encouragingly, the development of novel targeted therapy has been proved to have fewer side effects and has a more promising e cacy [2].Previous studies have reported that dabrafenib plus trametinib was a new therapy with clinically meaningful anti-tumor activity and a manageable safety pro le in patients with BRAF V600E non-small cell lung cancer (NSCLC).…”

“…The Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is detected in 8-10% of metastatic colorectal cancers (mCRCs) and is strongly correlated with patients' poor prognosis [5,6]. It was reported that patients with BRAF V600E mutation showed a poorer outcome than those with non-V600E mutations [7]. Recently, studies on therapies for BRAF-mutated mCRC patients have obtained several advances.…”

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

“…A breakthrough in understanding the pathogenesis of LCH occurred in 2010 when a gain-of-function mutation in B-RAF (V600E) was identified in more than half of LCH patient samples [21]. Similar to in melanoma [22], colon [23], and thyroid cancer [24], BRAF V600E marks poor outcomes. In a series of 315 children with LCH, the B-RAF V600E mutation was correlated with aggressive disease and resistance to chemotherapy [25].…”